Abstract
BackgroundThis study aimed to investigate the clinical and pathological characteristics, and the recurrence and prognostic factors of borderline ovarian tumors (BOTs).MethodsThe data of 286 patients admitted to hospital and followed up for more than ten months were analyzed retrospectively to study the clinicopathological characteristics and related factors of recurrence.ResultsThe median age of the patients was 42.06 ± 14.97 years, and the duration of the follow-up ranged from 10–109 months. During the follow-up period, 40 patients had a recurrence. Of these patients, 36 were ≤ 40 years, and patients with premenopausal recurrence accounted for 20.5% (36/176). In patients undergoing conservative treatment or radical operations, the recurrence rates were 21.3% and 1.8%, respectively, and they were 13.4% (36/268) in patients at Federation International of Gynecology and Obstetrics (FIGO) stage I, and 22.2% (4/18) in patients at an advanced stage. Postoperative pathology revealed that 40 patients had micropapillary tumors, among whom ten patients (25%) had a recurrence, and 19 patients had complications with interstitial infiltration. Of these 19 patients, six had a recurrence (31.5%). Another 22 patients had complications with calcified sand bodies; among these, eight patients (36.4%) had a recurrence. All the differences were statistically significant (P < 0.05). There were four cancer-related deaths during the follow-up period. Late FIGO stage, conservative operation, and a high level of carbohydrate antigen 125 (CA125) were independent risk factors for the recurrence of BOTs.ConclusionBOTs usually occur in women under 40 years, have an occult onset, and half of the patients have no obvious clinical manifestations. Serum CA125 level can be used as a tumor marker to detect BOTs and the risk of its recurrence. Operation mode and FIGO stage are important independent factors for the recurrence of BOTs.
Highlights
This study aimed to investigate the clinical and pathological characteristics, and the recurrence and prognostic factors of borderline ovarian tumors (BOTs)
It was found that the recurrence rate of BOTs was 13.9% (40/286)
The results revealed that the Federation International of Gynecology and Obstetrics (FIGO) stage, the type of operation, and serum carbohydrate antigen 125 (CA125) were independent risk factors for the recurrence of BOTs (Table 3)
Summary
This study aimed to investigate the clinical and pathological characteristics, and the recurrence and prognostic factors of borderline ovarian tumors (BOTs). Borderline ovarian tumors (BOTs) are ovarian tumors with growth patterns and cytological characteristics that fall between benign and malignant tumors, and nondestructive stromal infiltration. Prognosis is much better than that of ovarian cancer of the same clinical stage [1, 4]. BOTs account for 10%–15% of ovarian epithelial tumors, and their staging is based on the FIGO staging. At the time of diagnosis, 75% of patients with BOTs are at an early stage. A few patients are in the late stage at diagnosis [3]. Plasma mucinous tumors are mucinous cystadenoma that accounts for 20% of benign ovarian neoplasms.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have